Welcome to the POMALYST REMS® program

Important information about POMALYST® (pomalidomide) and the POMALYST Risk Evaluation and Mitigation Strategy (REMS) program

  • POMALYST is contraindicated in pregnant females and females capable of becoming pregnant. Females of reproductive potential may be treated with POMALYST provided adequate precautions are taken to avoid pregnancy

  • To avoid embryo-fetal exposure, POMALYST is only available under a restricted distribution program called "POMALYST REMS®"

  • Only prescribers and pharmacies certified by the POMALYST REMS® program can prescribe and dispense POMALYST to patients who are enrolled and meet all the conditions of the POMALYST REMS® program

The goals of the POMALYST risk evaluation and mitigation strategy are as follows:

  1. To prevent the risk of embryo-fetal exposure to POMALYST

  2. To inform prescribers, patients, and pharmacists on the serious risks and safe-use conditions
    for POMALYST

For additional information about the POMALYST REMS® program, please contact the Celgene Customer Care Center at 1-888-423-5436

Download the
Celgene REMS mobile app
for CelgeneRiskManagement.com
to your iPad here: